Ensysce Biosciences, Inc. Price & Performance (ENSC)

Ensysce Biosciences has raised $2.2 million via warrant exercises, providing critical funding for its pain management pipeline. Wall Street analysts now forecast an average one-year price target of $46.73, over 1,100% above current levels. The company maintains an "Outperform" rating, reflecting strong investor optimism despite ongoing volatility.12

Ensysce Biosciences’ stock soared 96% following news of a new opioid use disorder treatment patent. Despite the rally, the company remains in a long-term downtrend, with significant risks tied to clinical and regulatory hurdles. Investors are advised to remain cautious as volatility persists and profitability remains distant.34

Recent clinical trial advancements and a $1.1 million direct offering have fueled major price swings for Ensysce Biosciences. While promising results for its overdose-protection drug have sparked optimism, ongoing losses and the need for further capital highlight the speculative nature of this biotech’s future trajectory.56